Connecting Healthcare Professionals to Scientiﬁc Information
UCBCOMPASS® provides scientiﬁc education and
medical information on UCB medicines used to treat
certain immune-mediated inﬂammatory conditions.
UCB continues to proactively monitor the COVID-19 situation. To learn more about UCB's preparedness, click here.
FDA issues a Complete Response letter to the Biologics License Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis. Learn more.
The Women's Health Fellowship Program will begin accepting applications for the 2024-2025 fellowship year on May 8th. Learn More
Listen to Podcasts
Gain insights as scientists, medical experts, and patients discuss advances and unmet needs in inﬂammatory autoimmune conditions.
Review the latest UCB research, including original articles, from peer-reviewed sources.
Opportunities for Investigators
Submit a study concept, request access to patient-level data from UCB trials, or become a UCB clinical trial investigator.